Search

Displaying results 4611 - 4620 of 7540 in total
  1. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  2. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).

  3. Drug

    SCIB1

    go.drugbank.com/drugs/DB18439
    Investigational

    SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma. … It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.

  4. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    Trials of this drug have most likely been discontinued by the manufacturer. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  5. Drug

    (5E,7E,9)-decatrien-2-one

    go.drugbank.com/drugs/DB15618
    Experimental

    An compound produced by _Fomitopsis betulina_, an edible fungus commonly called the birch polypore. Similar to [(5Z,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116]

  6. Drug

    Patritumab

    go.drugbank.com/drugs/DB12090
    Investigational

    Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.

  7. Drug

    Thiabendazole

    go.drugbank.com/drugs/DB00730
    ApprovedVet approvedWithdrawn

    2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of P...

  8. Drug

    SO-101

    go.drugbank.com/drugs/DB05345
    Experimental

    SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. … Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.

  9. Drug

    Fluciclatide

    go.drugbank.com/drugs/DB14842
    Investigational

    The conditions targeted by [18F]Fluciclatide in these studies include high-grade glioma, lung cancer, and kidney neoplasms … Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.

  10. Drug

    Pradefovir mesylate

    go.drugbank.com/drugs/DB05478
    Investigational

    Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver. … As adefovir is poorly absorbed and associated with a high level of nephrotoxicity, pradefovir mesilate was designed to specifically target the liver and reduce risks to external tissue, especially the